Publications & Posters

Poster

Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

  • AUTHORS Pemmaraju, et al
  • Programs OPN-2853
Download PDF
Publication

PLX3397 inhibits the accumulation of intra-tumoral macrophages and improves bromodomain and extra-terminal inhibitor efficacy in melanoma

https://doi.org/10.1111/pcmr.12845
Publication

Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer

https://doi.org/10.1530/ERC-19-0107
Publication

The next-generation BET inhibitor, PLX51107, delays melanoma growth in a CD8-mediated manner

https://doi.org/10.1111/pcmr.12788
Publication

Inhibition of NF-κB-Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma

  • AUTHORS Ambrosini, et al
  • Programs OPN-51107
https://doi.org/10.1158/0008-5472.CAN-18-3177
Publication

Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma

https://doi.org/10.15252/emmm.201809081
Publication

BET Inhibition Modifies Melanoma Infiltrating T Cells and Enhances Response to PD-L1 Blockade

https://doi.org/10.1016/j.jid.2018.12.024
Publication

ETV6-NTRK3 induces aggressive acute lymphoblastic leukemia highly sensitive to selective TRK inhibition

  • AUTHORS Roberts, et al
  • Programs OPN-7486
https://doi.org/10.1182/blood-2018-05-849554
Publication

Blocking colony stimulating factor 1 receptor (CSF-1R) and tropomyosin receptor kinase A (TrkA) improves the antitumor efficacy of immune checkpoint blockade

  • AUTHORS Duffy, et al
  • Programs OPN-7486
https://www.jimmunol.org/content/200/1_Supplement/122.15/tab-article-info
Poster

Phase 1b/2a Study of PLX51107, a Small Molecule BET Inhibitor, in Subjects with Advanced Hematological Malignancies and Solid Tumors

  • AUTHORS Patnaik, et al
  • Programs OPN-2853
Download PDF